Published in final edited form as:

Vaccine. 2010 August 23; 28(37): 6028–6035. doi:10.1016/j.vaccine.2010.06.085.

Mutation Specific Control of BCR-ABL T315I Positive Leukemia with a Recombinant Yeast-Based Therapeutic Vaccine in a Murine Model

Melanie R Bui¹, Hodson Victoria², King Tom², Leopold Derek¹, Dai Shaodong¹, Fiolkoski Valerie², Oakes Sarah², Duke Richard², Apelian David², Franzusoff Alex², and James DeGregori¹

University of Colorado Denver School of Medicine, Department of Immunology, Department of Biochemistry and Molecular Genetics, L18-9103, Mail Stop 8101; P.O. Box 6511; Aurora, CO 80045

¹University of Colorado Denver School of Medicine, Aurora CO, USA

²GlobeImmune, Louisville, CO, USA

Abstract

Chromosomal translocations generating the *BCR-ABL* oncogene cause chronic myeloid leukemia (CML) and a subset of acute lymphoblastic leukemia. The *BCR-ABL*^{T315I} mutation confers drug resistance to FDA-approved targeted therapeutics imatinib mesylate, dasatinib, and nilotinib. We tested the ability of a recombinant yeast-based vaccine expressing the T315I-mutated *BCR-ABL* antigen to stimulate an anti-*BCR-ABL*^{T315I} immune response. The yeast-based immunotherapy significantly reduced or eliminated *BCR-ABL*^{T315I} leukemia cells from the peripheral blood of immunized animals and extended leukemia-free survival in a murine model of *BCR-ABL*⁺ leukemia compared to animals receiving sham injection or yeast expressing ovalbumin. With immunization, leukemic cells harboring *BCR-ABL*^{T315I} were selectively eliminated after challenge with a mixed population of *BCR-ABL* and *BCR-ABL*^{T315I} leukemias. In summary, yeast-based immunotherapy represents a novel approach against the emergence of cancer drug resistance by the pre-emptive targeted ablation of tumor escape mutants.

Keywords

T315I; BCR-ABL; Immunotherapy

Introduction

The *BCR-ABL* oncogene results from a chromosomal translocation at position t(9:22) (q34;q11) [1,2]. *BCR-ABL* is causal for chronic myelogenous leukemia (CML) and present in 20-40% of adults with acute lymphoblastic leukemia (ALL) [3-6]. CML and ALL result in a massive accumulation of clonal myeloid or lymphoid progenitor cells respectively. Untreated CML results in death at a median of 3 years after diagnosis, while the more aggressive ALL, results in death at a median of 11 months after diagnosis, even with

© 2010 Elsevier Ltd. All rights reserved.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

chemotherapy [6,7]. The targeted BCR-ABL kinase inhibitor, imatinib mesylate (M), achieves a complete cytogenetic response at 18 months in 76% of patients with CML [8-11]. However, after 3.5 years, ~16% of chronic phase CML patients relapse despite IM therapy. Most of these relapses are due to BCR-ABL point mutations that prevent IM binding and restore aberrant kinase activity [12,13]. The T315I mutation is a particularly relevant target, as this “gatekeeper” mutation occurs with the highest incidence (16%, [14-16]) and is the only point mutation causing cross-resistance to both IM and second generation kinase inhibitors [17-19].

Investigational approaches for drug-resistant leukemia treatment involve small molecule inhibitors effective against BCR-ABL^{T315I} and other drug escape mutations, inhibitors targeting effectors downstream of BCR-ABL, or drugs with epigenetic targets [20,21]. An attractive alternative would be to activate T cell immunity in CML or ALL patients against tumor cells expressing leukemia-specific or leukemia-associated antigens [22]. The mutated BCR-ABL^{T315I} protein is a tumor specific antigen, and thus is not subject to central self-tolerance mechanisms [23,24]. The activation of T cell immunity against imatinib escape mutants in combination with IM treatment could suppress or eliminate the emergence of resistant variants.

Immunotherapy with whole heat-killed recombinant Tarmogen® yeast delivering the target antigen activates a potent innate response to the yeast vector, plus an adaptive T cell immune response to the target antigen. Thus, immune recognition of the target antigen is directly coupled to the innate danger response against the yeast vector and uptake by phagocytic dendritic cells (DC), macrophages and neutrophils. Another advantage of this immunotherapy approach is the delivery of target polypeptides whose processing by host DCs affords a full spectrum of epitopes derived from the polypeptide, facilitating presentation of and response to epitopes relevant for each person’s HLA (MHC-I and MHC-II) receptor repertoire.

Immunization with GI-4000 Tarmogen® yeast elicits mutation-selective killing of tumors harboring the mutated Ras protein in a carcinogen-induced murine lung tumor model [25,26]. GI-4000 Tarmogen® yeast delivering mutated Ras polypeptides are being tested in clinical trials in patients with pancreas cancer, non-small cell lung cancer, and colorectal cancer. In those trials, the tumors are genotyped to establish the presence of *ras* mutations and to administer the GI-4000 Tarmogen® yeast product that would activate T cell immunity against the matched mutant Ras protein (e.g. ClinicalTrials.gov Identifier: NCT00300950). Given the immune activation against mutated Ras proteins using Tarmogen® yeast immunotherapy, we tested whether this approach would elicit T cell responses against the T315I mutation in BCR-ABL, for the purpose of preventing or limiting BCR-ABL^{T315I} IM drug-resistance.

2. Materials and methods

2.1. MHC-Binding Peptide Prediction Algorithms and REVEAL Assay

Eighty-one overlapping 8-10 amino acid peptides spanning BCR-ABL^{T315I} and two other BCR-ABL IM point mutations, E255K and M351T, were analyzed for potential CD8⁺ T cell epitopes. The MHC-binding peptide prediction algorithms, Arbmatrix[27], libscore[28], smm[29], arb[27], bimas[30], SYFPEITHI[31] and ann[32], were used to predict binding to the C57BL/6 and BALB/c MHC class I alleles; H-2D^b, H-2K^b, H-2D^d, H-2K^d and H-2L^d. Prediction software algorithms with accuracy scores estimated to be higher than 66.5% for any given allele were used for these analyses (Supplementary Fig. 1). The 62 highest scoring peptides were synthesized. These were evaluated using the REVEAL® *in vitro* H-2D^b and H-2K^b MHC class I-binding assays performed by Proimmune.

2.2. Computer Modeling

Crystal structures were used for generating the Kb/nanomeric peptide model (pdb 1VAC[33]) and the H-2K^b/octameric peptide model (2VAB[34]) by using the swiss pdb viewer program [35]. The initial amino acid conformations of the peptides were manually adjusted to avoid clashes. Energy minimization refinement was performed on the peptides in CNS [36]. The H-2K^b molecules were fixed in the refinement. The final models were inspected in O [37] on Silicon Graphics OCTANE2 Workstations.

2.3. Animals

Wild-type BALB/c and C57BL/6 mice were purchased from the National Cancer Institute or bred at the University of Colorado Denver School of Medicine. The Institutional Animal Care and Use Committee approved all experiments using mice.

2.4. Primary Leukemia Generation

Murine stem cell viruses (MSCV) were prepared by transient transfection of Phoenix-E cells together with pCL-Eco (encodes Gag, Pol and Env), and titred on fibroblasts using GFP or RFP as the marker BCR-ABL expression. Bone marrow cells were harvested from C57BL/6 or BALB/c mice and enriched for CD117⁺ cells by MACS® (Miltenyi Biotec, Bad Gladback, Germany). The cells were first cultured overnight in DMEM plus 10% defined fetal bovine serum with the cytokines hSCF (gift from Dr. Chris Hogan, UC Denver), hIL-11, mIL-3, and hIL-6 (PeproTech, Rocky Hill, New Jersey, USA). The cells were infected for 6 hrs with 6 µl/ml Polybrene (Sigma) and supernatants containing MSCV-ires-GFP or MSCV-ires-RFP viruses encoding p210 *BCR-ABL* or p210 *BCR-ABL*^{T315I} (the drug resistant mutant was a gift from Drs. Michael Deininger and Brian Druker, Oregon Health Sciences University). The cells were then transplanted intravenously into sublethally irradiated (3 Gy) mice using an X-ray source (RadSource RS2000 irradiator). Infection efficiencies were determined after culturing aliquots of transduced cells under HSC conditions for 48-72 hours [38]. Primary leukemias expressing BCR-ABL or BCR-ABL^{T315I} developed with similar kinetics between 3-8 weeks. Transplanted mice were monitored for disease development, as judged by increasing percentages of GFP or RFP expressing cells with blast morphology in peripheral blood of transplanted animals, as well as symptoms, such as reduced mobility, hunching, and labored breathing. Moribund animals were sacrificed and leukemias were characterized and stored at -80°C. Automated hematocrit analysis of peripheral blood was performed using a Cell-Dyn 1700 System (Abbott, Abbott Park, IL, USA).

2.5. Yeast Vaccine

Immunotherapy constructs were made by subcloning the *BCR-ABL* junction, SH3, SH2 and kinase domains by blunt end ligation into the pBlueScript SKII-® vector (Fermentas) and introducing point mutations using sequential QuikChange Site Directed Mutagenesis Kit® (Stratagene). To avoid triggering a xenogeneic immune response of the human Abl protein by the murine immune system, two amino acids were altered to match the mouse *ABL* sequence ortholog (Fig. 1a). The altered *ABL* sequence spanning just downstream of the junction epitope through the region encoding the three escape mutant epitopes was cloned into the Tarmogen® expression plasmid under control of a strong constitutive promoter (Fig. 1a). A C-terminal hexahistidine tag was added for detection and quantification. The cloned DNA Inserts were bidirectionally sequenced and the plasmid was transfected into *S. cerevisiae* yeast (W303alpha) using the EZ yeast transfection kit (Zymo research). Transfectants were selected on solid medium lacking uracil and growth of cultures was in medium containing 20 g/L glucose, 6.7 g/L yeast nitrogen base, and 2 mg/mL each of adenine, histidine, tryptophan, and leucine. Liquid yeast cultures were grown to mid-

exponential phase, harvested by centrifugation, washed once in PBS, and heat inactivated at 56°C for 1h. The yeast were washed three times in PBS and re-suspended in PBS at 20 YU/mL (1 YU = 10⁷ Tarmogen® yeast cells). Tarmogen® yeast (5YU) were injected subcutaneously at 2 sites per immunization. Dosing was administered 10, 8, 6 and 1 weeks prior to leukemia challenge. The parental yeast vector expressing an irrelevant antigen, chicken ovalbumin (yeast^{OVA}) was used as a control immunogen [39].

2.6. Detection of Abl T315I protein by western blotting

The expression of Abl protein by yeast^{T315I} was quantified by western blotting using an anti-(His)₆ tag monoclonal antibody. Additional positive identification of the expressed protein was conducted by immunoblotting with a monoclonal antibody recognizing the SH2 domain of the Abl protein (Mouse Anti-ABL Monoclonal Antibody 554148, BD Pharmingen).

2.7. Challenge with Primary Leukemias

Primary leukemia cells (1.7 × 10⁵ GFP⁺ or RFP⁺ cells) suspended in 200 µl IMDM/1% FBS were used for challenging vaccinated or control recipient mice, which resulted in leukemia development in most control recipients between 10 and 14 days post transfer. Challenged mice were monitored at least once per day for secondary leukemia development as described above.

2.8. Flow cytometric analysis

Tail blood, spleen and bone marrow cells were isolated, and the contributions of BCR-ABL expressing cells to hematopoiesis as well as developing leukemias was determined using flow cytometry. Single-cell suspensions of hemolysed bone marrow, spleen or peripheral blood were washed in PBS containing 1% BSA (PBS/1% BSA), and resuspended in PBS/1% BSA plus 5% supernatant from hybridoma cells producing the 2.4G2 monoclonal antibody against the Fc receptor. Cells were stained in 20 µl of antibody for 20 min at room temperature. Cells were washed once with 1 ml of PBS/1% BSA and resuspended in 400 µl of PBS/1%BSA/2mM EDTA for flow cytometric analysis. Fluorescence was detected with CyAn (DAKO, Carpinteria, CA, USA) or Cell Quanta SC MLP (Beckman Coulter, Allendale, New Jersey, USA) cytometers. PE-conjugated α-H-2L^d/D^b (43-1-2S) and PE-conjugated α-H-2K^d/D^d/K^b (28-14-8) were used for MHC class I expression studies.

2.9. Statistical analysis

Statistical analysis was performed using GraphPad Prism 4 software. Asterisks represent p values of 2-tailed t-tests. “*” is used for p<0.05, “**” for p<0.01, and “***” for p<0.001. The development of fatal leukemias was plotted on Kaplan/Meier curves, and the statistical significance of yeast^{T315I} therapy was determined using the logrank test.

3. Results

3.1. BCR-ABL^{T315I} peptides bind MHC class I

The BCR-ABL^{E255K}, BCR-ABL^{T315I} and BCR-ABL^{M351T} mutations are the three most common BCR-ABL mutations conferring resistance to IM found in treated patients (Fig. 1a) [40]. Prior to testing *in vivo*, overlapping 8-10 amino acid peptides spanning the drug-resistance mutations BCR-ABL^{E255K}, BCR-ABL^{T315I} and BCR-ABL^{M351T} (Fig. 1a) were analyzed using MHC-binding peptide prediction algorithms to identify peptides able to be presented to CD8⁺ T cells (Supplementary Fig. 1). Mutant epitopes with sufficient binding affinity to be detected were identified in an *in vitro* MHC class I binding assay (Proimmune, REVEAL®). Both C57BL/6 MHC class I alleles were tested. None of the peptides were

found to bind H-2D^b (Fig. 1b). Six BCR-ABL^{E255K} peptides and six BCR-ABL^{T315I} peptides were found to bind the H-2K^b MHC class I allele (Fig. 1c), while none of the BCR-ABL^{M351T} peptides were of sufficient binding affinity in this assay to be scored positively. When H-2K^b binding BCR-ABL^{T315I} peptides were graphed, they exhibited a bell-shaped normal Gaussian distribution with an R² of 0.8364 (Supplementary Fig. 2) indicating that of the T351I peptides tested, those with an asparagine carboxy terminal cleavage site were optimal and deviations from this position impaired peptide binding. Computer modeling simulations were consistent with binding of T315I peptides IIIIEFMTY and YIIIEFMTY to the H-2K^b allele (Fig. 2a), with the 315I mutant amino acid facing the TCR in P3 or P4 respectively (Fig 2b). These results indicated that peptides framing the BCR-ABL^{T315I} mutation were likely to be presented to CD8 T cells by activated DCs in the C57BL/6 mouse strain. The clinically significant BCR-ABL^{T315I} mutation was pursued in the remaining experiments, given that this common mutation confers resistance to all approved BCR-ABL kinase inhibitors.

3.2. Primary leukemia challenge into immunocompetent recipients

A model system for testing the immunogenicity of the T315I mutation was developed to be compatible with BCR-ABL⁺ leukemogenesis, a full vaccination course and an intact immune system. Murine BCR-ABL⁺ leukemias were produced by retroviral transduction of the full length p210 BCR-ABL gene into donor bone marrow stem and progenitor cells followed by a sublethal irradiation and subsequent bone marrow transplant [41]. Murine recipients of BCR-ABL transduced stem and progenitor cells developed BCR-ABL primary leukemias. Since immune system disruptions would interfere with vaccine experiments, we tested whether leukemias could be transferred into unconditioned recipients. Consistent with previous reports, our primary leukemias could not be initiated in unconditioned recipient mice [42,43]. However, transfer of some established primary leukemias consistently caused fully penetrant secondary leukemias in unconditioned recipient mice (Fig 3a). Not all primary BCR-ABL leukemias produced a secondary leukemia in non-irradiated recipient mice (unpublished observations). Therefore, only fully penetrant primary leukemias were used in the following studies.

3.3. Vaccination with yeast^{T315I} significantly extends leukemia-free survival

Recombinant *S. cerevisiae* Tarmogen® yeast were engineered to express a mutated ABL^{T315I} polypeptide (yeast^{T315I}, Fig. 4a). Tarmogen® yeast vaccination caused mild injection site reactions, in the form of pruritis and resolvable skin lesions, in a subset of C57BL/6 mice (Fig. 4b). No side-effects were observed in the BALB/c background (data not shown).

For vaccine efficacy experiments, primary leukemias co-expressing BCR-ABL^{T315I} and GFP were generated in C57BL/6 mice and harvested as described in the Methods. Vaccinated and control mice were challenged with a homogeneous population of Gr-1^{neg}, B220⁺, BCR-ABL^{T315I} leukemia (Fig. 5a and 5b). Leukemia development was monitored by flow cytometric analysis of the peripheral blood. Animals succumbed to the leukemia, typically evidenced by hind limb paralysis just prior to sacrifice, within 10-25 days after challenge. The development of secondary leukemias was confirmed upon autopsy with complete blood counts together with flow cytometry for GFP and hematopoietic lineage markers in the spleen and bone marrow (data not shown).

Administration of yeast^{T315I} significantly extended survival in C57BL/6 mice upon challenge with BCR-ABL^{T315I} expressing leukemias, compared to untreated (P=0.0037) and yeast^{OVA}-treated (P=0.0104) controls (Fig. 5c). Vaccination with yeast^{OVA} resulted in a significant increase in peripheral blood CD8⁺ T cells specific for the OVA peptide,

SIINFEKL, presented on H-2K^b (data not shown). Surviving yeast^{T315I} treated mice had no detectable leukemia upon autopsy even 2 months post-challenge (data not shown). In confirmation of this result, the peripheral circulation of BCR-ABL^{T315I} cells at day 10 after challenge was reduced or eliminated in immunized, but not control, C57BL/6 animals ($P < 0.0018$) (Fig. 5d). These results highlighted the T315I mutation-selective immune response that was elicited by administration of yeast^{T315I}.

Antigen specific anti-leukemic responses were reproduced with several secondary leukemias. In one case, however extended leukemia free survival of vaccinated mice was not observed (Supplementary Fig. 3a). Nonetheless, even for this leukemia, yeast^{T315I} vaccinated mice had a reduced leukemic burden in the peripheral blood early in the course of the disease (Supplementary Fig. 3b).

A common mechanism of immune evasion by cancer cells is MHC class I downregulation. Therefore, we confirmed that the primary leukemias used for challenge expressed MHC class I and that they responded normally to IFN- α by up-regulating expression on the cell surface (Supplementary Fig. 4a and 4b). Additionally, H-2Kb expression was assessed on secondary leukemias from moribund vaccinated and control mice. No significant difference was found between these groups, suggesting that immune evasion via MHC class I loss could not account for leukemic progression in some of the vaccinated mice (Supplementary Fig. 5).

3.4. Vaccination with yeast^{T315I} selectively eliminates BCR-ABL^{T315I} cells in the presence of wild-type BCR-ABL leukemia cells

In order to better reflect the development of clinical drug resistance, where a subpopulation of leukemia cells express the drug resistance mutation, vaccinated and control BALB/c mice were challenged with a mixed population of 63% wild-type BCR-ABL (BCR-ABL^{WT}) and 37% drug-resistant BCR-ABL^{T315I} leukemias (Fig. 6a and 6b). As BALB/c mice express different MHC Class I molecules as compared to C57BL/6 mice, these experiments also address whether the T315I containing peptide can be presented by other MHC haplotypes. Primary leukemias were Gr-1^{neg} and B220⁺ (data not shown). Upon leukemia development in recipient mice, the number of leukemic cells harboring BCR-ABL^{T315I} was significantly reduced ($P < 0.05$) relative to cells expressing BCR-ABL^{WT} in the spleen and bone marrow of mice administered the yeast^{T315I} vaccine. Sixty-eight percent antigen-specific elimination of leukemic cells was observed in the spleen (Fig. 6c and 6d) and 71.88% specific lysis in the bone marrow (Fig. 6e). These results indicate that immune protection was targeted against the single amino acid alteration in the mutated BCR-ABL^{T315I} protein expressed by the leukemia cells. Additionally, given that vaccination with yeast^{T315I} resulted in the specific elimination of BCR-ABL^{T315I}-expressing leukemic cells, we can infer that peptides spanning T315I can also be presented on BALB/c MHC alleles (of the d haplotype).

4. Discussion

The dramatic improvement in CML treatment with targeted therapies such as IM has been accompanied by the development of drug-resistant escape mutations, much like that found upon small molecule drug inhibition of viral replication. Rational prevention of drug resistance has the potential to prolong the efficacy of available drugs and improve clinical outcomes. Thus, similar to HAART for control of HIV infection, effective cancer therapy may necessitate innovative combination treatments. Experiments described here address the problem of drug escape mutations using an immune-mediated approach that may complement IM, dasatinib, or nilotinib therapy. Mutation-selective immune responses targeting BCR-ABL^{E255K}, BCR-ABL^{T315I} and BCR-ABL^{M351T} could eliminate drug resistant leukemia clones when they are clinically silent. Thus, the incidence of relapse due

to drug-resistance may decrease if leukemia patients taking IM or one of its derivatives are effectively immunized against the BCR-ABL^{T315I} antigen or other drug escape epitopes. In this study, we have demonstrated that immunization with Tarmogen® yeast^{T315I} activates protective immunity against challenge with BCR-ABL^{T315I} expressing leukemia.

By transferring fully penetrant leukemias into vaccinated mice, we were able to assess the efficacy of yeast^{T315I} vaccination, but our experimental design was constrained by the lack of a transferrable chronic phase model with slow kinetics. Thus, our experiments tested vaccine efficacy using an aggressive blast crisis leukemic challenge, for which immunotherapy post-leukemic challenge is not feasible. The immune response induced by yeast^{T315I} vaccination had only a median of 13.5 days to eliminate a rapidly expanding, aggressive leukemic population, as opposed to a clinical setting where an immune response could have years over which to either prevent emergence or to eliminate the minimal residual disease found in CML patients undergoing IM therapy. The 32% long-term leukemia free survival observed in yeast^{T315I} vaccinated mice (Fig. 5c) is striking when considering the aggressiveness of the blast crisis leukemia model and may be even more effective against the more indolent chronic phase disease observed in the setting of IM treated CML.

Patients developing IM drug-resistance start out either with no resistant variants prior to IM treatment or with a low frequency drug-resistant population that expands over time while under IM selection. We attempted to more accurately model the latter situation by challenging with a mixed population of drug-susceptible and drug-resistant leukemias. Additionally, we were interested in whether or not we could see antigen specific elimination of BCR-ABL^{T315I} leukemia cells in a strain other than C57BL/6. Therefore, we challenged vaccinated and control BALB/c mice with a heterogeneous population of BCR-ABL and BCR-ABL^{T315I} leukemia cells. Yeast^{T315I} vaccinated BALB/c mice were able to selectively reduce the BCR-ABL^{T315I} cells in the presence of BCR-ABL cells suggesting that the single amino acid BCR-ABL^{T315I} mutation is antigenic in the BALB/c background as well as in the C57BL/6 strain. These results highlight two independent lines of evidence from these studies for the activation of mutation-selective immunity in this murine leukemia model, with two different mouse strains. The sum of the results reflect the potential for BCR-ABL⁺ leukemia treatment benefit following immunization of Tarmogen® yeast^{T315I} in a diverse population of subjects.

To our knowledge, the BCR-ABL^{T315I} tumor specific antigen is the first drug-resistance antigen to be targeted by vaccination. We have shown that several peptides bearing the BCR-ABL^{T315I} point mutation bind H-2K^b *in vitro*, likely, in such a way as to present the mutant isoleucine facing a CD8⁺ T cell receptor. We have expressed the BCR-ABL^{T315I} antigen in a safe and immunostimulatory yeast vaccine vector [39], and have shown antigen specific reductions in leukemia cells in the peripheral blood. Moreover, vaccination increased leukemia-free survival after challenge with BCR-ABL^{T315I} leukemia. In addition, yeast^{T315I} vaccination successfully reduced the drug-resistant leukemic burden in two mouse strains. In summary, yeast^{T315I} vaccination represents a novel approach against the emergence of IM resistance in BCR-ABL⁺ leukemias and potentially could be used to prevent the emergence of resistance to other selective cancer therapies.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The MSCV *BCR-ABL*^{T315I} drug resistant mutant construct was kindly provided by Drs. Michael Deininger and Brian Druker. We thank Kavita Tundwal for her assistance with cloning and mutagenesis, John Kappler for help with the H-2Kb peptide binding prediction models, the University of Colorado Flow Cytometry Core including Karen Helm, Christine Childs and Lester Acosta, and Vadym Zaberezhnyy for assistance with mouse symptom surveillance and leukemia harvesting. This work was supported in part by GlobeImmune. JD was also supported by the National Institutes of Health (RO1-CA109657) and MRB was supported in part by the Cancer Research Institute Predoctoral Emphasis Pathway in Tumor Immunology Fellowship.

References

- [1]. Nowell P, Hungerford D. A minute chromosome in human chronic granulocytic leukemia. *Science*. 1960; (132):1488–501. [PubMed: 17739576]
- [2]. Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. *Nature*. Jun 1; 1973 243(5405):290–3. [PubMed: 4126434]
- [3]. Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. *N Engl J Med*. Oct 13; 1988 319(15):990–8. [PubMed: 3047582]
- [4]. Maurer J, Janssen JW, Thiel E, van Denderen J, Ludwig WD, Aydemir U, et al. Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction. *Lancet*. May 4; 1991 337(8749):1055–8. [PubMed: 1673492]
- [5]. Westbrook CA, Hooberman AL, Spino C, Dodge RK, Larson RA, Davey F, et al. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). *Blood*. Dec 15; 1992 80(12):2983–90. [PubMed: 1467514]
- [6]. Gleissner B, Gokbuget N, Bartram CR, Janssen B, Rieder H, Janssen JW, et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. *Blood*. Mar 1; 2002 99(5):1536–43. [PubMed: 11861265]
- [7]. Sawyers CL. Chronic myeloid leukemia. *N Engl J Med*. Apr 29; 1999 340(17):1330–40. [PubMed: 10219069]
- [8]. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. *N Engl J Med*. Apr 5; 2001 344(14):1038–42. [PubMed: 11287973]
- [9]. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. *N Engl J Med*. Mar 13; 2003 348(11):994–1004. [PubMed: 12637609]
- [10]. Quintas-Cardama A, Cortes J. Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy? *Curr Oncol Rep*. Sep; 2009 11(5):337–45. [PubMed: 19679008]
- [11]. Quintas-Cardama A, Kantarjian H, Cortes J. Imatinib and beyond—exploring the full potential of targeted therapy for CML. *Nat Rev Clin Oncol*. Sep; 2009 6(9):535–43. [PubMed: 19652654]
- [12]. Shah NP, Sawyers CL. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. *Oncogene*. Oct 20; 2003 22(47):7389–95. [PubMed: 14576846]
- [13]. Williams RT, Sherr CJ. The INK4-ARF (CDKN2A/B) locus in hematopoiesis and BCR-ABL-induced leukemias. *Cold Spring Harb Symp Quant Biol*. 2008; 73:461–7. [PubMed: 19028987]
- [14]. Nicolini FE, Corm S, Le QH, Sorel N, Hayette S, Bories D, et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). *Leukemia*. Jun; 2006 20(6):1061–6. [PubMed: 16642048]
- [15]. Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. *Clin Cancer Res*. Dec 15; 2006 12(24):7374–9. [PubMed: 17189410]

- [16]. Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O'Brien S, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. *Leukemia*. Oct; 2006 20(10):1767–73. [PubMed: 16855631]
- [17]. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. *N Engl J Med*. Jun 15; 2006 354(24):2531–41. [PubMed: 16775234]
- [18]. Kantarjian H, Giles F, Wunderle L, Bhatta K, O'Brien S, Wassmann B, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. *N Engl J Med*. Jun 15; 2006 354(24):2542–51. [PubMed: 16775235]
- [19]. Azam M, Nardi V, Shakespeare WC, Metcalf CA 3rd, Bohacek RS, Wang Y, et al. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. *Proc Natl Acad Sci U S A*. Jun 13; 2006 103(24):9244–9. [PubMed: 16754879]
- [20]. de Lavallade H, Khorashad JS, Davis HP, Milojkovic D, Kaeda JS, Goldman JM, et al. Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation. *Blood*. Oct 1; 2007 110(7):2779–80. [PubMed: 17881650]
- [21]. Quintas-Cardama A, Cortes J. Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. *Clin Cancer Res*. Jul 15; 2008 14(14):4392–9. [PubMed: 18628453]
- [22]. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. *Blood*. Jul 1; 2006 108(1):28–37. [PubMed: 16522812]
- [23]. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. *Cancer Cell*. Aug; 2002 2(2):117–25. [PubMed: 12204532]
- [24]. Roche-Lestienne C, Preudhomme C. Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment. *Semin Hematol*. Apr; 2003 40(2 Suppl 2):80–2. [PubMed: 12783380]
- [25]. Lu Y, Bellgrau D, Dwyer-Nield LD, Malkinson AM, Duke RC, Rodell TC, et al. Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy. *Cancer Res*. Aug 1; 2004 64(15):5084–8. [PubMed: 15289309]
- [26]. Munson. Coupling Innate and Adaptive Immunity with Yeast-Based Cancer Immunotherapy. 2008.
- [27]. Bui HH, Sidney J, Peters B, Sathiamurthy M, Sinichi A, Purton KA, et al. Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. *Immunogenetics*. Jun; 2005 57(5):304–14. [PubMed: 15868141]
- [28]. Udaka K, Wiesmuller KH, Kienle S, Jung G, Tamamura H, Yamagishi H, et al. An automated prediction of MHC class I-binding peptides based on positional scanning with peptide libraries. *Immunogenetics*. Aug; 2000 51(10):816–28. [PubMed: 10970096]
- [29]. Peters B, Tong W, Sidney J, Sette A, Weng Z. Examining the independent binding assumption for binding of peptide epitopes to MHC-I molecules. *Bioinformatics*. Sep 22; 2003 19(14):1765–72. [PubMed: 14512347]
- [30]. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. *J Immunol*. Jan 1; 1994 152(1):163–75. [PubMed: 8254189]
- [31]. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. *Immunogenetics*. Nov; 1999 50(3-4):213–9. [PubMed: 10602881]
- [32]. Vladimir Brusic GR, Leonard C. Harrison Prediction of MHC Binding Peptides Using Artificial Neural Networks. *Complexity International*. April.1995 :02. 1995.
- [33]. Fremont DH, Matsumura M, Stura EA, Peterson PA, Wilson IA. Crystal structures of two viral peptides in complex with murine MHC class I H-2Kb. *Science*. Aug 14; 1992 257(5072):919–27. [PubMed: 1323877]

- [34]. Fremont DH, Stura EA, Matsumura M, Peterson PA, Wilson IA. Crystal structure of an H-2Kb-ovalbumin peptide complex reveals the interplay of primary and secondary anchor positions in the major histocompatibility complex binding groove. *Proc Natl Acad Sci U S A*. Mar 28; 1995 92(7):2479–83. [PubMed: 7708669]
- [35]. Kaplan W, Littlejohn TG. Swiss-PDB Viewer (Deep View). *Brief Bioinform*. May; 2001 2(2): 195–7. [PubMed: 11465736]
- [36]. Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. *Acta Crystallogr D Biol Crystallogr*. Sep 1; 1998 54(Pt 5):905–21. [PubMed: 9757107]
- [37]. Jones TAZJ-Y, Cowan SW, Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. *Acta Crystallographica Section A*. 1991; 2(42):110–9.
- [38]. Bilousova G, Marusyk A, Porter CC, Cardiff RD, DeGregori J. Impaired DNA replication within progenitor cell pools promotes leukemogenesis. *PLoS Biol*. Dec.2005 3(12):e401. [PubMed: 16277552]
- [39]. Stubbs AC, Martin KS, Coeshott C, Skaates SV, Kuritzkes DR, Bellgrau D, et al. Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. *Nat Med*. May; 2001 7(5):625–9. [PubMed: 11329066]
- [40]. O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. *Cancer Res*. Jun 1; 2005 65(11):4500–5. [PubMed: 15930265]
- [41]. Van Etten RA. Studying the pathogenesis of BCR-ABL+ leukemia in mice. *Oncogene*. Dec 9; 2002 21(56):8643–51. [PubMed: 12476310]
- [42]. Williams RT, Roussel MF, Sherr CJ. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. *Proc Natl Acad Sci U S A*. Apr 25; 2006 103(17):6688–93. [PubMed: 16618932]
- [43]. Mumprecht S, Schurch C, Schwaller J, Solenthaler M, Ochsenbein AF. Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. *Blood*. Aug 20; 2009 114(8):1528–36. [PubMed: 19420358]
- [44]. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. *Nature*. Feb 9; 2006 439(7077):682–7. [PubMed: 16382236]
- [45]. Hsieh CS, Macatonia SE, O'Garra A, Murphy KM. T cell genetic background determines default T helper phenotype development in vitro. *J Exp Med*. Feb 1; 1995 181(2):713–21. [PubMed: 7836924]
- [46]. Loke P, Allison JP. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells *Proc. Natl Acad Sci U S A*. Apr 29; 2003 100(9):5336–41.

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

Fig. 6.